"Gov. Gavin Newsom recently signed a bill to fast-track the study of psychedelic drugs, which a coalition of veterans say hold enormous potential to treat post-traumatic stress disorder and depression. More veterans die from suicide in America on a daily basis than average daily combat deaths in Vietnam, Iraq and Afghanistan combined, according to data collected by the Department of Veterans Affairs. A growing number of former service members are now turning to psychedelics to treat the mental health conditions caused by wartime trauma and traumatic brain injury."
"The nonprofit organization Veterans Exploring Treatment Solutions is a big believer in the power of psychedelic therapies such as ibogaine, which co-founder and former Navy SEAL Marcus Capone credits with saving his life. This legislative cycle, VETS sponsored Assembly Bill 1103 to eliminate roadblocks to approve the study of psychedelics in California. "After 13 years as a Navy SEAL and multiple deployments, I tried every conventional therapy available - none worked for me," Capone said in a statement. "Ibogaine gave me my life back. With AB 1103, California is leading - empowering researchers to advance rigorous studies with the urgency this work warrants." AB 1103 targets the Research Advisory Panel of California, which is responsible for approving any studies involving the administration of Schedule 1 and 2 drugs after they have received approval from the Food and Drug Administration."
California enacted legislation to accelerate clinical research into psychedelic drugs for mental health conditions including post-traumatic stress disorder and depression. A coalition of veterans and the nonprofit Veterans Exploring Treatment Solutions support psychedelic therapies such as ibogaine and sponsored Assembly Bill 1103 to remove approval roadblocks. Veteran suicide rates exceed the average daily combat deaths from recent wars, heightening urgency. AB 1103 targets the Research Advisory Panel process for studies involving Schedule I and II drugs after FDA approval. Most psychedelics remain Schedule I despite growing veteran interest and reported therapeutic benefits.
Read at Los Angeles Times
Unable to calculate read time
Collection
[
|
...
]